eating disorders | CARLAT PUBLISHING

RESEARCH UPDATE

SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

October 1, 2022

Dr. Feder, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.

Addressing Weight Stigma in Clinical Practice

September 19, 2022

Joshua Feder, MD and Mara Goverman

Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can lethal.

Diagnosing and Treating Avoidant/Restrictive Food Intake Disorder

August 8, 2022

Joshua Feder, MD, Mara Goverman, and Jennifer Thomas, PhD

Nine years after DSM-5, Avoidant Restrictive Food Intake Disorder (ARFID) is still settling into clinical practice. Dr. Jennifer Thomas helps sort out the differential diagnosis between ARFID, anorexia, and other conditions and plan treatment in the context of comorbid conditions, such as anxiety disorders and Autism Spectrum Disorder.

RESEARCH UPDATE

New Canadian Eating Disorders Guidelines

March 12, 2021

John Raiss, MD

John Raiss, MD Dr. Raiss has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What is the best approach to treatment of adolescents with eating disorders? What level of care should be we advocating for to have the best chance of a good outcome? This review of the recent Canadian Eating Disorders Guidelines offers a clear direction for our efforts to provide better care.

RESEARCH UPDATE

Olanzapine for Anorexia Nervosa

November 15, 2019

Kristen Gardner, PharmD.

Kristen Gardner, PharmD. Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A randomized, double- blind, placebo-controlled trial studying the effects of olanzapine on change in body weight and obsessionality in adult outpatients with anorexia nervosa. Although strength of the study includes its large sample size, it is undetermined if patient weight gain is due to a therapeutic effect on anorexia or to olanzapine’s known metabolic effects.